Psoriasis treatment bimekizumab maintains high Levels of skin clearance
pharmafile | August 9, 2021 | News story | Sales and Marketing |
New two-year data has shown that bimekizumab maintained high Levels of skin clearance in patients with moderate to severe plaque psoriasis.
Data presented showed that the majority of patients who achieved complete or near complete skin clearance after 16 weeks of bimekizumab treatment maintained these responses through to two years with continuous maintenance dosing, every four weeks (Q4W) or every eight weeks (Q8W).
The efficacy and safety of bimekizumab have not been established and it is not approved by any regulatory authority worldwide.
Mark Lebwohl, Dean for Clinical Therapeutics, Icahn School of Medicine at Mount Sinai, and Chairman emeritus, Kimberly and Eric J Waldman Department of Dermatology and Presenting Author of the data at the AAD Summer Meeting, said: “These interim results from the BE BRIGHT study highlight the potential of bimekizumab to provide lasting skin clearance to adults living with moderate to severe plaque psoriasis.
“These data are meaningful for the dermatology community and further add to the clinical evidence we have from the bimekizumab Phase III clinical program.”
Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of US, UCB, said: “Given the chronic nature of psoriasis, physicians and patients value treatment options that can offer long-term disease control.
“We are pleased to share the first presentation of bimekizumab data from the BE BRIGHT study highlighting the potential of bimekizumab to provide complete skin clearance that can last through to two years in adult patients with moderate to severe plaque psoriasis.”
Bimekizumab is currently under review by the FDA for the treatment of moderate to severe plaque psoriasis in adults.
On June 25th, 2021, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending granting a marketing authorisation for bimekizumab for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
The final decision of the European Commission on marketing authorisation is expected within approximately two months of the CHMP opinion.
Lilly Subbotin
